EGFR and non-small cell lung carcinoma: Among driver targetable mutations, Epidermal Growth Factor Receptor (EGFR) mutations can be found in approximately 10–16% of NSCLC patients from Western countries, and this percentage is even larger when only considering Asian patients (up to 50%) [2].